Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023. In the quarter to June 2026, EPS grew 85.6% and free cash flow fell 19.6%, each against the same quarter a year earlier.
Follow AZTR
Azitra, Inc. (AZTR) P/E ratio
As of 14 October 2026, Azitra, Inc. (AZTR) trades at a P/E ratio of 1.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 2.8× (August 2026); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OSRH OSR Health, Inc. compare | n/m |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | 0.0× |
| AZTR Azitra, Inc. | 1.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)